Table 2.

Multivariate Analysis for Baseline Characteristics Associated with Predominantly Persistent Intraretinal Fluid through Year 1

Baseline Characteristics			Predominantly Persistent Intraretinal Fluid through Yr 1
		n	Yes (%)	Adjusted Odds Ratio (95% CI)*	P
Drug	Bevacizumab	175	68 (38.9%)	Ref.	< 0.001
	Ranibizumab	173	36 (20.8%)	0.4 (0.3–0.7)
Visual acuity, baseline	≥ 68 letters, 20/40 or better	120	23 (19.2%)	Ref.	0.01*
	53 to 67 letters, 20/50 to 80	134	45 (33.6%)	2.1 (1.1–3.7)
	38 to 52 letters, 20/100 to 160	75	28 (37.3%)	2.4 (1.2–4.7)
	< 38 letters, 20/200 or worse	19	8 (42.1%)	2.9 (1.0–8.1)
Epiretinal membrane	No	297	81 (27.3%)	Ref.	0.02
	Yes	51	23 (45.1%)	2.2 (1.2–4.2)

CI = confidence interval; Ref. = reference.

^*P value calculated considering category order of baseline visual acuity.